About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT03610373

Testing Psychosocial Treatment Planning Methods for Youth Anxiety and Depression

Youth depression and anxiety represent a serious public health concern, with affected youth often experiencing social, familial, and academic impairment. Research evidence supports a growing array of ...

Lead sponsor: Boston University Charles River Campus•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Boston University Charles River Campus

Collaborators

National Institute of Mental Health (NIMH)

Age

7 - 15 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•a current DSM-5 principal diagnosis of a Major Depressive Disorder, Dysthymic Disorder, Generalized Anxiety Disorder, Separation Anxiety Disorder, Social Phobia, or Specific Phobia
•if receiving psychiatric medication, dose will be stable for at least 3 months at enrollment with ability to maintain medication
•youth and caregiver speak fluent English

Exclusion Criteria

•active suicidality
•history of severe physical or mental impairments (e.g., mental retardation, autism spectrum disorders) in youth or caregiver
•participation in additional psychosocial treatment

Related studies

RECRUITINGPhase 3

Ketamine Augmentation of ECT in Treatment-Resistant Depression

NCT07088380 · Major Depressive Disorder, Treatment Resistant Depression

RECRUITINGPhase 2

Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)

NCT06843187 · Major Depressive Disorder(MDD), Insomnia Comorbid to Psychiatric Disorder

RECRUITINGPhase 3

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

NCT07227454 · Depressive Disorder, Major

RECRUITINGPhase 3

"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder"

NCT06564818 · Major Depressive Disorder

Efficacy of a Transdiagnostic Group Treatment for Emotional Disorders Applied in Blended Format: a Controlled Study.

NCT05569018 · Anxiety Disorders, Depressive Disorders

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 28, 2020Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment45

Start dateOct 2016

Last updatedJan 28, 2020

Condition

Anxiety Disorders Depressive Disorder

Locations shown

Boston University

Boston, Massachusetts

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 28, 2020Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions